Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Business sectors
- biotechnology [1]
- Company / filing name
- Intellia Therapeutics, Inc. [2]
- Headquarters location
- Cambridge [1]
- Founded
- 2014 [1]
- Legal form
- public limited company [1]
- Official website
- intelliatx.com ↗ [1]
- ISIN (reported securities)
- US45826J1051 [1]
- CIK
- 1652130 [2]
- Country in background record
- United States [1]
- Symbols / exchanges
- NTLA (Nasdaq) [2]
Company positioning and business
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. [3]
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. [3]
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Lonvo-z is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 3 studies. [3]
Background text: Wikipedia contributors, Intellia Therapeutics. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Financial year, securities and disclosures
Listed securities: NTLA (Nasdaq). Multiple symbols may represent different share classes or securities of the same registrant. [2]
History and key events
Founding / inception date recorded in Wikidata. [1]
Financial results and regulatory disclosures
No individual financial documents have been indexed yet. Open the source to consult company disclosures. [2]
Related entities and concepts
Frequently asked questions
When was Intellia Therapeutics, Inc. founded?
Founded: 2014. The linked source provides the background record. [1]
Where is the headquarters of Intellia Therapeutics, Inc.?
Headquarters location: Cambridge. The linked source provides the background record. [1]
Which business sectors are recorded for Intellia Therapeutics, Inc.?
Business sectors: biotechnology. The linked source provides the background record. [1]
Sources and review dates
- Wikidata — company background record (CC0) ↗
- Company identity and profile data ↗
- Wikipedia contributors — Intellia Therapeutics (CC BY-SA 4.0) ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.